Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
- Details
- Category: Bayer
Bayer Schering Pharma announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar® (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin™ - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in
Berlin, Germany.
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress
- Details
- Category: Bayer
Bayer Schering Pharma announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar® (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin™ - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.
U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine.
Novartis investigational bronchodilator QAB149 compared to tiotropium
- Details
- Category: Novartis
Novartis has announced results from Phase III trials showing QAB149 (indacaterol), an investigational once-daily bronchodilator for chronic obstructive pulmonary disease (COPD), significantly improves lung function[3] and provides a significant reduction in breathlessness[1] compared to tiotropium, a current treatment option.
Appeals Court Affirms Patent Infringement Rulings Against Roche's peg-EPO Product
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) has announced that the Court of Appeals for the Federal Circuit affirmed the Massachusetts District Court's decision that Roche's peg-EPO product, Mircera, infringes four Amgen patents ('868, '698, '933 and '422) relating to recombinant erythropoietin (EPO) and processes for making it.
Lilly Unveils Blueprint for Speeding Innovative Medicines to Patients
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) has unveiled a new operating model and announced a series of changes to speed medicines from its pipeline to patients. To help achieve this goal, the company will establish a Development Center of Excellence to streamline and accelerate late-stage development of new medicines, and will reorganize its pharmaceutical business into four business units that will operate alongside the Elanco animal health business unit.
Two new studies report increased survival rates in Tamiflu-treated patients
- Details
- Category: Roche
Tamiflu (oseltamivir) demonstrated significantly improved survival rates in patients with the highly pathogenic H5N1 influenza (avian flu) and severe cases of seasonal influenza, according to two new studies presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco.(1,2)
More Pharma News ...
- Abbott Announces Approval in China for Next-Generation XIENCE V(R) Drug Eluting Stent
- New data show patients with chronic low back pain maintained pain reduction on duloxetine
- Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology
- FDA Advisory Committee makes favorable recommendation for Cervarix
- Online Video Library Launched To Share Martha Beck's Experience Living with Fibromyalgia
- Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek
- Shantha Biotechnics Awarded Large Vaccine Contracts by United Nations Agency